An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimer’s drug lecanemab shows “clinical benefit” for the treatment of the disease, paving the way for the medication to be considered for full FDA approval. A decision from the FDA is expected by July 6. Lecanemab, a monoclonal antibody sold under the brand name Leqembi, is one of the first dementia drugs that appears to slow the progression of cognitive decline.
, the FDA says. Some people who get appeared to be higher in people who had a gene called APOE4, which can raise the risk of Alzheimer’s disease or other dementias.
Source: Healthcare Press (healthcarepress.net)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA panel recommends injectable drug to prevent RSV in infantsThe monoclonal antibody shot would be given to babies during or before their first RSV season, as well as to high-risk children up to age 2 entering their second RSV season.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Eisai-Biogen Alzheimer's Drug Data Confirms Benefits: FDAUS Food and Drug Administration staff on Wednesday said data from a late-stage trial of Eisai and Biogen's Alzheimer's disease drug suggests it offered a meaningful benefit to patients.
Source: Medscape - 🏆 386. / 55 Read more »
FDA panel weighs US approval for Alzheimer's drug from Eisai and BiogenA panel of expert advisers on Friday began their meeting to discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.
Source: Reuters - 🏆 2. / 97 Read more »
Friday marks WSFA’s annual Summer Fund and Food DriveFriday marks WSFA 12 News’ annual Summer Fund and Food Drive, and we can’t wait to see you as we gather food and money to benefit the Montgomery Area Food Bank!
Source: wsfa12news - 🏆 338. / 59 Read more »
Alzheimer’s advocates rally for Medicare coverage of newly approved FDA treatmentsNew treatments for Alzheimer’s are on the market, but the price tag is making them inaccessible. The new treatments are not covered by Medicare or Medicaid, which is something the Alzheimer’s Association is trying to change.
Source: wrtv - 🏆 598. / 51 Read more »
FDA Finalizes Limit on How Much Arsenic Can Be in Apple JuiceFederal regulators have finalized new guidance on how much inorganic arsenic can be present in apple juice, in an effort to limit the exposure of infants and young children to this environmental contaminant.
Source: WebMD - 🏆 709. / 51 Read more »